HIIT in Youth With Congenital Heart Disease (MedBIKE)
NCT04575883
Recruiting
Congenital heart disease (CHD), the most common birth defect, is present in nearly 1% of the population. CHD patients are associated with intense resource utilization and premature death in adulthood. The risk of premature death is linked with reduced exercise capacity, a finding consistently noted in youth with CHD. Reduced exercise capacity in this population has also been associated with reduce physical activity and health-related quality of life. Cardiac rehabilitation (CR) in adults with a... Read More
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
12/19/2024
Locations: University of Alberta, Edmonton, Alberta
Conditions: Congenital Heart Disease, Pediatric ALL
Register for Updates
Reducing Pain and Anxiety During Dressing Changes After Burn Surgery Using Virtual Reality
NCT04820400
Recruiting
Burn injury and its treatment is an intensely painful experience. Most severely injured patients require numerous dressing changes and skin grafting procedures (removing skin from healthy part of the body and moving it to damaged area of the body). This procedure cause extensive pain and anxiety and many patients can become dependent on pain killers during their hospital stay and throughout rehabilitation. This can delay reintegration into society and increase the chance of opioid dependence. An... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Sunnybrook Research Institute, Toronto, Not set
Conditions: Pain, Postoperative, Trauma, Burns
Register for Updates
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
NCT05145127
Recruiting
Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008. Study B7841005: approximately 145 adolescent and adult participants 12 to \<75 years of age with severe hemophilia A or moderately severe to severe hemophilia B (defined as FVIII activity \<1% or FIX activity ≤2%, respectivel... Read More
Gender:
MALE
Ages:
Between 1 year and 74 years
Trial Updated:
12/19/2024
Locations: University of Iowa, Iowa City, Iowa +59 locations
Conditions: Hemophilia A, Hemophilia B
Register for Updates
Simulation for Operating Room Ergonomics
NCT05541354
Recruiting
Ergonomics is the study of how people interact with, and work within an environment. This idea is especially important in a setting such as the operating room (OR), which can be both physically and mentally challenging. Poor ergonomic practices lead to physical discomfort and injuries in \>50% of OR staff (surgeons, anesthesiologists, and nurses), impacting OR staff quality of life and leading to staff burnout and early retirement. The end result of which is reduced access to care for patients.... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/19/2024
Locations: Sunnybrook Research Institute, Toronto, Not set
Conditions: Occupational Injuries
Register for Updates
Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation
NCT05738148
Recruiting
When a baby is born with a low heart rate or no heart rate, the clinical team must provide breathing support and chest compressions (what is call cardiopulmonary resuscitation or CPR). In some situations, the clinical team also need to give medications to help the heart rate increase. During CPR, the most common medication given is called epinephrine. There is another medication called vasopressin that is available that could be beneficial to newborn babies. However, no study has compared epinep... Read More
Gender:
ALL
Ages:
Between 0 minutes and 20 minutes
Trial Updated:
12/19/2024
Locations: Royal Alexandra Hospital, Edmonton, Alberta
Conditions: Cardiac Arrest Neonatal
Register for Updates
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NCT05890677
Recruiting
The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Harvard Medical School, Boston, Massachusetts +29 locations
Conditions: Lymphedema, Breast Cancer
Register for Updates
A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD
NCT06205095
Recruiting
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and to explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: St. Michael's Hospital, Toronto, Ontario
Conditions: Von Willebrand Diseases
Register for Updates
Evaluation of Technological Innovation in Radiotherapy
NCT03378856
Recruiting
Prospective cohort study of patients receiving standard-care radiotherapy is paramount to a better understanding of radiation effects and longterm outcomes. The primary objective is to determine the feasibility of establishing infrastructure to systematically collect clinical data, patient-reported outcomes, and imaging data from daily radiotherapy practice. Secondary objectives are to provide a control cohort for comparative effectiveness research of investigational interventions through a cm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: London Health Regional Cancer Centre, London, Ontario +4 locations
Conditions: Cancer, Radiotherapy Side Effect
Register for Updates
Patient-oriented Randomized Pragmatic Feasibility Trial with RTMS in Depression and Anxiety
NCT05028738
Recruiting
This trial compares intermittent theta-burst stimulation (iTBS) to low frequency repetitive transcranial magnetic stimulation (LFR) in regards to depression and anxiety outcomes in 100 patients with treatment resistant depression (TRD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Non-Invasive Neurostimulation Therapies (NINET) Laboratory, UBC Department of Psychiatry, Vancouver, British Columbia
Conditions: Major Depressive Episode, Major Depressive Disorder
Register for Updates
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
NCT05156983
Recruiting
The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa inhibitors who require urgent surgery/invasive procedure. The participant will be assigned by chance to either TAK-330 or SOC 4F-PCC as part of standard treatment before surgery. Patients participating in this study will need to be hospitalize... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of California Davis Health System, Sacramento, California +48 locations
Conditions: Coagulation Disorder
Register for Updates
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +218 locations
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075
Recruiting
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +184 locations
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates